An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence After Administration of "DWJ1445" and "DWC202506" in Healthy Adults
Latest Information Update: 09 Dec 2025
At a glance
- Drugs DWJ-445 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 09 Dec 2025 New trial record